| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7390388 | Value in Health Regional Issues | 2015 | 7 Pages |
Abstract
The TGA will approve oncologics that offer potentially substantial clinical benefits on the basis of an indirect comparison of single-arm trials but at a delay versus the EMA and the FDA. The PBAC reimbursement approval also requires more rigorous supportive clinical data and acceptable cost-effectiveness as demonstrated on a cost-benefit or cost-quality-adjusted life-year metric.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Richard PhD, Mohammad Kashif MPharm, Samuel PhD,